|
Company
|
KitoZyme
|
|
Address
|
Parc industriel des Hauts-Sarts Zone 2 Rue Haute Claire, 4
4040 HERSTAL
BELGIQUE
|
|
Phone
|
+32 4 259 85 00
|
|
Fax
|
+32 4 259 85 09
|
|
VAT number
|
BE-473676932
|
|
Email
|
v.maquet@kitozyme.com
|
|
Website
|
http://www.kitozyme.com/
|
|
Contact
|
MAQUET Véronique
|
|
Activity sector
|
- Biotech Products
- Medical Devices
|
|
Expertise sector
|
- Drug Delivery
- Gene/cell therapy
- Vaccine
- Dermatology
- Commercialization
- Development
- Manufacturing and distribution
|
|
Activity
|
KitoZyme is an expert and manufacturer of specialty ingredients for high added-value markets, in particular dedicated to well-being, nutrition and therapeutic solutions.
Keen to get away from traditional chitosan production using crustacean shells, KitoZyme’s patented technology enables, for the first time, the production of high-purity chitin-glucan and chitosan exclusively from renewable, safe, non-GMO and traceable fungal sources. For the pharmaceutical, biotechnology and medical device markets, KitoZyme is manufacturing and supplying non-animal, cGMP ultra-pure chitosan, KiOmedine®, at large-scale. This ultra-pure chitosan features remarkable characteristics: 100% animal-free, outstanding traceability, high control on molecular characteristics, high purity and safety profile, strong documentation, high safety and consistent performances, thus overcoming some of the drawbacks of shellfish-derived ultra-pure chitosan. KiOmedine® sets a new benchmark and triggers new developments in therapeutic areas, including wound & haemostasis, biosurgery, scaffold & cell therapy, drug delivery & vaccines.
KitoZyme also offers pharmaceutical, biotechnology and medical device companies long-term supply agreements and R&D partnership opportunities; founded on and profiting from the company’s team of scientific, process and business development experts in biopolymer chemistry, formulation, processing, process scale-up and analytics.
|
|
Products
|
Through its ultra-pure chitosane, KiOmedine-CsU®, KitoZyme is highly active in the pharmaceutical and biomedical fields. KitoZyme is also extending its product portfolio by developing new chitosan derivates that have modified properties compared to chitosan.
|
|